The cell's own logistics system becomes a vulnerability.
Cancer's ability to resist treatment has long been one of medicine's most humbling adversaries, but a team at Harrington Discovery Institute has traced a critical vulnerability to an unexpected place: the cell's own internal shipping system. By mapping how Golgi apparatus proteins ferry growth factor receptors to the cell surface — where they receive the signals that drive uncontrolled tumor growth — researchers have identified a new class of targets that could work alongside existing therapies. Published in Science Signaling, the findings offer a potential answer to one of oncology's most persistent questions: not just how to block cancer's signals, but how to disrupt the machinery that delivers them.
- Drug resistance remains one of the most devastating patterns in cancer care — therapies that work brilliantly at first eventually fail as tumors evolve workarounds, leaving patients with fewer options.
- The discovery centers on Golgi proteins acting as a cellular postal service, packaging and delivering growth factor receptors — like EGFR in lung cancer and HER2 in breast cancer — to the cell surface where they ignite tumor growth.
- Crucially, this mechanism sits upstream of where most current therapies intervene, meaning it could be targeted to prevent or delay resistance rather than simply react to it.
- Harrington Discovery Institute, with 227 medicines in development and 24 drugs already in clinical trials, has the translational infrastructure to move this laboratory finding toward actual patients.
- The research reframes the therapeutic battlefield: instead of only jamming cancer's signals, medicine may soon be able to disrupt the logistics network that makes those signals possible.
Cancer cells are stubborn — they grow where they shouldn't and find ways around the treatments designed to stop them. A team led by Seth J. Field at Harrington Discovery Institute may have identified a crucial piece of why.
The story begins with growth factor receptors, proteins that sit on cell surfaces like antennas waiting for signals to divide. In lung cancer, the epidermal growth factor receptor drives the disease; in breast cancer, HER2 plays a central role. Modern therapies have learned to block these receptors — and for a time, it works. But in most patients, the cancer eventually develops resistance, and the disease returns.
Field's team asked a more fundamental question: how do these dangerous receptors reach the cell surface in the first place? Their answer, published in Science Signaling, points to the Golgi apparatus — the cell's internal shipping department. A set of proteins within this structure packages growth factor receptors and delivers them to the cell membrane. Without this delivery mechanism, receptors never arrive. Without receptors on the surface, growth signals can't get through.
Previous research had linked these Golgi proteins to lung, breast, and colorectal cancers, but their precise function was unclear. Field's team resolved that ambiguity: these proteins are the delivery system. And that clarification opens a new angle of attack. If cancers can evolve resistance to therapies targeting the receptors themselves, disrupting the upstream machinery that transports those receptors could offer a complementary — and potentially more durable — strategy.
The Harrington Discovery Institute, now in its 13th year, is positioned to pursue that work. With 227 medicines in development across 75 institutions and 24 drugs in clinical trials, it has the pipeline to carry a laboratory insight toward patients. For those living with advanced-stage cancers, the prognosis remains difficult — but each discovery that exposes a new vulnerability in cancer's own logistics makes the path forward a little clearer.
Cancer cells are stubborn. They grow where they shouldn't, resist the drugs designed to stop them, and find ways around the treatments that once worked. For decades, researchers have chipped away at understanding why—and a team at Harrington Discovery Institute may have just identified a crucial piece of the puzzle.
The problem starts with growth factor receptors, proteins that sit on the surface of cells like tiny antennas, waiting for signals to grow. When these receptors get activated, they tell the cell to divide and multiply. In lung cancer, the epidermal growth factor receptor drives the disease. In breast cancer, HER2 does much of the damage. Modern therapies have learned to jam these signals—blocking the receptors or the growth factors that activate them. For a while, it works. But in most patients, the cancer eventually figures out how to resist the treatment, and the disease roars back.
What researchers led by Seth J. Field at the Harrington Discovery Institute wanted to know was simpler: how do these dangerous receptors even get to the cell surface in the first place? The answer, published in Science Signaling on May 19, points to a cellular structure called the Golgi apparatus—essentially the cell's shipping department. Inside this compartment, a set of proteins acts like a postal service, packaging up growth factor receptors and ferrying them to the cell membrane. Once the receptors arrive at their destination, they're ready to receive growth signals and trigger the cascade of events that leads to tumor formation.
This wasn't entirely new territory. Previous studies had flagged these Golgi proteins as contributors to common cancers—lung, breast, colorectal. But their exact function remained murky. Field's team clarified it: these proteins are the delivery mechanism. Without them, growth factor receptors can't reach the surface. Without receptors on the surface, growth signals can't get through. The cell can't be told to grow uncontrollably.
The implications are significant because they suggest a new angle of attack. If existing therapies target the receptors themselves or the growth factors that activate them, what happens when cancer cells evolve resistance to those drugs? The answer may lie upstream, in the machinery that gets the receptors there in the first place. By identifying these Golgi proteins as essential players, the researchers have essentially drawn a map of an alternative route—a new class of therapeutic targets that could work alongside current treatments, potentially preventing or delaying the emergence of drug resistance.
Field emphasized that this kind of fundamental discovery is what fuels medical progress. The next phase is the hard part: turning this understanding into actual drugs. The Harrington Discovery Institute, now in its 13th year, has the infrastructure to pursue that work. The institute currently supports 227 medicines in development across 75 institutions, has launched 46 companies, and has 24 drugs in clinical trials. It's the kind of pipeline that can take a laboratory finding and move it toward patients.
For people living with advanced-stage cancers, the prognosis remains grim. But the path forward is becoming clearer. Each discovery that illuminates how cancer cells survive and resist treatment is another opportunity to outmaneuver them. This one points to a vulnerability in the cell's own logistics system—a place where the machinery that enables cancer might be interrupted before it even begins.
Notable Quotes
These proteins assist the movement of growth factor receptors to the cell surface, where they are activated by growth factors and signal cells to grow uncontrollably and form tumors.— Seth J. Field, MD, PhD, Harrington Discovery Institute
Discoveries in fundamental biology are the fuel that enables advances in medicine.— Seth J. Field
The Hearth Conversation Another angle on the story
So these Golgi proteins—they're not the receptors themselves, they're the delivery system?
Exactly. The receptors are the problem, but they can't cause trouble if they never reach the cell surface. These proteins are like the trucks in a warehouse. No trucks, no delivery.
And cancer cells need them to work normally?
Yes. The receptors have to get to the surface to receive growth signals. It's a fundamental cellular process. The cancer cells aren't doing anything exotic—they're just using the cell's own machinery more aggressively.
So why hasn't anyone targeted this before?
They didn't fully understand what these proteins were doing. They knew they were involved in cancer, but the mechanism was unclear. Once you know the mechanism, you can design drugs against it.
Does this mean current therapies will suddenly work better?
Not immediately. But it opens a door. If you block the receptors and the cancer develops resistance, maybe blocking the delivery system too would prevent that resistance from emerging. It's about layering defenses.
How long until there's an actual drug?
That's the real question. The science is solid, but drug development takes years. The institute has the resources to move fast, but there are no guarantees.